Nsg2 Inhibitors
Chemical inhibitors of Nsg2 can affect its function through various molecular pathways by targeting different enzymes that regulate its activity. Staurosporine acts as a broad-spectrum protein kinase inhibitor, which means that it can inhibit a wide range of kinases that Nsg2 may rely on for its activation or stability within the cell. Similarly, Chelerythrine, Go6983, and Bisindolylmaleimide I specifically target protein kinase C (PKC), a family of kinases that are potentially involved in the phosphorylation and subsequent activation of Nsg2. By hindering PKC's activity, these inhibitors can directly decrease the functional activity of Nsg2. LY294002 and Wortmannin both target phosphoinositide 3-kinases (PI3Ks), which are implicated in multiple signaling pathways. Inhibition of PI3K by these chemicals can suppress the activation of downstream targets that may include Nsg2, thus indirectly reducing its activity.
In addition to these, there are inhibitors that target the mitogen-activated protein kinase (MAPK) pathway, which is another regulatory pathway that Nsg2 may be a part of. U0126 and PD98059 are two such inhibitors that specifically inhibit MEK1/2, which is an upstream activator of extracellular signal-regulated kinases (ERKs). The inhibition of MEK by these chemicals can lead to decreased activation of ERK and subsequent downstream targets, potentially including Nsg2. JNK and p38 MAP kinases are also part of the MAPK family, and their inhibition by SP600125, SB203580, and PD169316 can also lead to decreased Nsg2 activity. These inhibitors can disrupt the signaling cascade that leads to the activation of stress response pathways, which may involve Nsg2. Lastly, PP2, as an Src family kinase inhibitor, can inhibit the activity of Src family kinases, which are known to regulate various signaling pathways. The inhibition of these kinases can reduce the functional activity of Nsg2 due to the potential involvement of Src family kinases in its regulation. Through these diverse mechanisms, each chemical inhibitor can contribute to the modulation of Nsg2's activity in the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases, which Nsg2 may interact with or depend on for its activation or stabilization within the cell. By inhibiting these kinases, Staurosporine can reduce the functional activity of Nsg2. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC), and PKC inhibition can lead to decreased phosphorylation and activation of downstream proteins, which can include Nsg2, thus functionally inhibiting Nsg2. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-PKC inhibitor that can prevent PKC-mediated signaling processes. Since Nsg2 may be regulated by PKC-dependent pathways, Go6983 can inhibit Nsg2 activity by blocking PKC function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and PI3K is involved in a number of signaling cascades that could regulate Nsg2 activity. By inhibiting PI3K, LY294002 can decrease the activation of Nsg2 that is PI3K-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1/2, which is upstream of ERK in the MAPK pathway. As Nsg2 may be functionally regulated by the MAPK pathway, U0126 can inhibit the activity of Nsg2 by blocking MEK1/2 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor, which can block the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can reduce the functional activity of proteins such as Nsg2 that are regulated by MAPK/ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which could be involved in the regulation of Nsg2. By inhibiting JNK, SP600125 can inhibit the functional activity of Nsg2 that is regulated by JNK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. p38 MAP kinase is involved in stress response pathways, and by inhibiting this kinase, SB203580 can reduce the functional activity of proteins like Nsg2 that may be regulated by p38 MAPK activation. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
PD169316 is another inhibitor of p38 MAP kinase. By blocking p38 MAPK, PD169316 can inhibit the activation of downstream proteins, potentially including Nsg2, thus functionally inhibiting Nsg2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting this kinase, Wortmannin can inhibit downstream signaling pathways that regulate the activity of proteins such as Nsg2, leading to functional inhibition of Nsg2. | ||||||